Diabetic Retinopathy
Welcome,         Profile    Billing    Logout  
 75 Companies   41 Products   41 Products   45 Mechanisms of Action   404 Trials   29684 News 
487 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Diabetic Retinopathy
ChiCTR-TRC-12002122: Clinical study of Treatment with kudiezi Injection in nonproliferative diabetic retinopathy Patients

Completed
4
80
 
1. Therapy for diabetes mellitus: To control blood glucose, blood pressure, and serum lipid through drug, dietary management, exercise and education, taking calcium dobesilate tablets. 2 kudiezi injection. ;Basic therapy and placebo: 1. Therapy for diabetes mellitus: To control blood glucose, blood pressure, and serum lipid through drug, dietary management, exercise and education, taking calcium dobesilate tablets; 2. placebo
The Eye Hospital of Xingtai; The Eye Hospital of Xingtai, self-raised funds
nonproliferative diabetic retinopathy
 
 
ChiCTR-TRC-11001220: Study of Evaluation on the Clinical Efficacy of Tradition Chinese Medcine in the treatment of Non-proliferative diabetic retinopathy

Completed
4
60
 
Formula of T.C.M: benefit qi nourish Yin formula (granule ), 4.5g, oral, tid. Placebo:simulation formula(granule), 4.5g, oral, tid. ;Method:1.The period of alternate treatment uses the formula of T.C.M and placebo itself before and after cross-over study design. Each patient will receive two treatment matching cycle .The time of one treatment matching cycle is ten weeks. Each treatment matching cycle is made up of two treatment phase, including formula of T.C.M and placebo . Each treatment phase is made up of two period,the first period is medication period from 1st to 4th week, the second period
Chengdu University of Traditional Chinese Medicine; Level of the institution：, The Eleventh Five-year Plan Project of the Ministry of Science and Technology of China
Non-proliferative diabetic retinopathy
 
 
ChiCTR-TRC-12001975: Study on Efficacy and Safety of Treatment with Compound Danshen Dripping Pills (CDDP) in Type 2 diabetes

Completed
4
1500
 
Compound Danshen Dripping Pills (CDDP) ;Conventional treatment, not taking the compound Danshen Dripping Pill
Shengjing Hospital of China Medical University, and Affiliated Hospital of Liaoning University of Chinese Traditional Medicine; Shengjing Hospital of China Medical University, Tianjin Tasly pharmaceutical CO., LTD
diabetic retinopathy and / or diabetic nephropathy.
 
 
2013-004934-14: EVEROLIMUS VERSUS MYCOPHENOLIC ACID IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE DIFFERENCES IN RETINAL NEOVASCULARIZATION IN PATIENTS WITH DIABETIC RETINOPATHY EVEROLIMUS VERSUS MYKOFENOLOVÁ KYSELINA U PACIENTŮ PO KOMBINOVANÉ TRANSPLANTACI LEDVINY A SLINIVKY BŘIŠNÍ ZA ÚČELEM ZHODNOCENÍ VÝVOJE NOVOTVORBY CÉV NA SÍTNICI U PACIENTŮ S DIABETICKOU RETINOPATIÍ

Ongoing
4
60
Europe
Certican, Myfortic, Tablet, Certican, Myfortic
Institut klinické a experimentální medicíny, Institut klinické a experimentální medicíny
simultaneous pancreas/kidney allograft transplantation simultánní transplantace pankreatu a ledviny, simultaneous pancreas/kidney allograft transplantation simultánní transplantace pankreatu a ledviny, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04]
 
 
ChiCTR-IPR-16007848: A Randomized Controlled Trial of Conbercept Pretretreatment before Vitrectomy in Proliferative Diabetic Retinopathy

Completed
4
100
 
intravitreal conbercept injection
The First People's Hospital of Yunnan Province; The First People's Hospital of Yunnan Province, topic fund
diabetic retinopathy
 
 
ChiCTR-TRC-14005224: The Comparison of effects between Continuous Subcutaneous Insulin Infusion and add-on therapy with sitagliptin in Patients with newly diagnosed Type 2 Diabetes Mellitus

Recruiting
4
60
 
CSII alone ;CSII combined with sitagliptin
The Third Affiliated Hospital of Southern Medical University; Level of the institution：, the Science and Technology Commission of Guangdong Province, China
diabetes
 
 
2015-000959-24: Investigation of Eylea for patients with diabetic macular edema in an outpatient Setting.

Ongoing
4
50
Europe
Eylea, Injection, Eylea
Abteilung für Augenheilkunde, AKH Linz, Bayer
Diabetic Retinopathy and diabetic macular edema are leading causes for visual loss and blindness in young adults around the world., Diabetic Macular Edema, Diseases [C] - Eye Diseases [C11]
 
 
2014-005700-24: Cytokine Levels within patients with diabetic macular edema.

Ongoing
4
20
Europe
Lucentis, Ozurdex, EMEA/H/C/000715, EU/1/10/638/001, Injection, Intravitreal implant in applicator, Lucentis, Ozurdex
Abteilung für Augenheilkunde, AKH Linz, Bayer
Diabetic Retinopathy and diabetic macular edema are leading causes for visual loss and blindness in young adults around the world., Diabetic Macular Edema, Diseases [C] - Eye Diseases [C11]
 
 
2006-000082-10: The efficacy of oral transmucosal fentanyl as an analgesic agent during pan retinal photocoagulation (Pilot Study)

Ongoing
4
38
Europe
Oral transmucosal fentanyl, Actiq,
Aintree University Hospitals NHS Trust
Diabetic retinopathy - the commonest cause of blindness in the working age group in the United Kingdom. Retinal photocoagulation is a painful procedure, which forms the mainstay of treatment of diabetic retinopathy.
 
 
2017-000250-19: Effect of calcium dobesilate in early stages of diabetic retinopathy Efecto del dobesilato de calcio en estadios precoces de retinopatía diabética

Ongoing
4
60
Europe
Calcium dobesilate monohydrate, Capsule, Doxium 500
Fundació Hospital Universitari Vall d'Hebron - Institut de Recersa (VHIR), VIFOR OM PHARMA
Diabetic retinopathy Retinopatía diabética, Diabetic retinopathy Retinopatía diabética, Diseases [C] - Eye Diseases [C11]
 
 
ChiCTR-IIR-17010747: Effect study of Yuanqi Quyu Decoction on proliferative diabetic retinopathy after vitrectomy surgery

Recruiting
4
70
 
vitrectomy surgery with 2 months oral Yuanqi Quyu Decoction ;vitrectomy surgery only
Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region; Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region, Science and Technology Department of Urumqi
proliferative diabetic retinopathy
 
 
Conber-PDR, ChiCTR-IIR-17014160: Comparing different day regimes of preoperative Conbercept administration in proliferative diabetic retinopathy patients undergoing vitrectomy: a prospective randomized controlled clinical triaDat

Recruiting
4
120
 
Intravitreous injection of Conbercept 1 day before vitrectomy ;Intravitreous injection of Conbercept 3 days before vitrectomy ;Intravitreous injection of Conbercept 5 days before vitrectomy ;Intravitreous injection of Conbercept 7 days before vitrectomy ;Sham intravitreous injection of Conbercept 3 days before vitrectomy ;patients with macular hole receiving vitrectomy
The first affiliated hospital of Nanjing Medical University; The first affiliated hospital of Nanjing Medical University, National Key R&D Program of China (2017YFA0104101)
diabetic retinopathy
 
 
ChiCTR1800015751: Intravitreal conbercept at the end of diabetic vitrectomy for prevention of postoperative vitreous hemorrhage in proliferative diabetic retinopathy.

Recruiting
4
30
 
conbercept injection after surgery ;no injection after surgery
Eye and ENT hospital, Fudan University; Eye and ENT hospital, Fudan University, Bethune foundation
diabetic retinopathy
 
 
ChiCTR1800019292: A study for the effect of Jiahua Tablets on non-proliferative retinopathy of type 2 diabetes

Recruiting
4
80
 
Basic treatment + Jiahua Tablets ;Basic treatment
Affiliated Hospital of Nanjing University of Chinese Medicine(Jiangsu Province Hospital of Chinese Medicine); Level of the institution：, Innovative development funding of Affiliated Hospital of Nanjing University of Chinese Medicine (Y2018CX10)
diabetic retinopathy
 
 
ChiCTR-OPN-17011519: A prospective, controlled clinical trial of pharmacokinetics following subretinal and intravitreous anti-VEGF treatment

Recruiting
4
50
 
vitrectomy with saline tamponade and subretinal anti-VEGF injection ;vitrectomy with saline tamponade and intravitreous anti-VEGF injection ;vitrectomy with silicone oil tamponade and intravitreous anti-VEGF injection ;vitrectomy with gas tamponade and intravitreous anti-VEGF injection ;intravitreous anti-VEGF injection
Shanghai Jiaotong University Affiliated Ninth People's Hospital; Shanghai Ninth People’s Hospital, National Natural Science Foundation of China
diabetic retinopathy
 
 
ChiCTR2000031400: Evaluate the effect of anti VEGF injection on postoperative vitreous rebleeding during perioperative period of proliferative diabetic retinopathy

Recruiting
4
86
 
Ranibizumab ;none
Shanxi Eye Hospital; Shanxi Eye Hospital, Key Research and Development (R&D) Projects of Shanxi Province (201803D31184)
Diabetic Retinopathy
 
 
ChiCTR1900024203: Analysis of differences between preoperative and postoperative application of Conbercept in high-risk diabetic retinopathy patients without macular edema

Recruiting
4
100
 
Anti-vegf drugs were followed by PRP ;PRP, anti-vegf drug when necessary
Shandong Eye Institute; Shandong Eye Institute, Chengdu Kanghong Pharmaceutical Group Co.,Ltd.
diabetic retinopathy
 
 
ChiCTR2300067476: Study on the Effect of Different anti-VEGF drugs on Fibrovascular Membrane of Proliferative Diabetic Retinopathy

Completed
4
24
 
Ranibizumab ;Conbercept ;Aflibercept
Tianjin Medical University Eye Hospital; Tianjin Medical University Eye Hospital, Self-financing
diabetic retinopathy
 
 
NCT04464694: Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema

Not yet recruiting
4
142
RoW
Ranibizumab, Lucentis, Sham injection, Pars plana vitrectomy, Vitrectomy
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Novartis
Proliferative Diabetic Retinopathy, Diabetic Macular Edema
12/21
06/22
ChiCTR1900026328: Effect of Calcium Dobesilate on the Retinal Microcirculation and function in Patients with Diabetic Retinopathy

Recruiting
4
80
 
oral intake of Calcium Dobesilate，0.5g per time, 3 times per day for 12 weeks ;oral intake of placebo ,one capsule per time, 3 times per day for 12 weeks
Department of Ophthalmology, Guangdong Provincial People's Hospital; Department of Ophthalmology, Guangdong Provincial People's Hospital, Bethune-Merck Diabetes Research Fund
diabetic retinopathy
 
 
NCT04362241: DEXTENZA VS. PREDNISOLONE ACETATE 1% Macular Edema With Diabetic Retinopathy After Cataract Surgery

Recruiting
4
30
US
Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE], Prednisolone Acetate 1%
Ophthalmic Consultants of the Capital Region
Retinopathy, Diabetic
02/22
03/22
ChiCTR2100043399: A prospective randomized controlled study of long-acting dexamethasone implant to improve the prognosis of PDR patients after vitrectomy

Recruiting
4
75
 
Ozurdex ;anti-VEGF drugs ;no
Tianjin Medical University Eye Hospital; Tianjin Medical University Eye Hospital, Self-financing
diabetic retinopathy
 
 
OPEAXE, ChiCTR2000036080: Evaluation of the efficacy of dexamethasone sustained-release implant (Ozurdex) in patients with proliferative diabetic retinopathy complicated with diabetic macular edema (vitrectomy / silicone oil filling and silicone oil removal) in combination

Not yet recruiting
4
200
 
Intraoperative dexamethasone sustained release implant ;none
Beijing aier intech eye hospital; Beijing aier intech eye hospital, Self-financing
Diabetic retinopathy
 
 
NCT05832996: Cool vs Room-temperature Artificial Tears

Completed
4
124
US
Refresh Plus Preservative-free Lubricant Eye Drops
University of Iowa
Diabetic Retinopathy With Macular Edema of Both Eyes (Diagnosis), Central Retinal Vein Occlusion With Macular Edema, Exudative Age-Related Macular Degeneration, Unspecified Eye, Cystoid Macular Edema, Ocular Surface Disease, Dry Eye Sensation, Eye Pain
07/22
07/22
ChiCTR2000035032: Efficacy of different doses of anti-VEGF with vitrectomy in the treatment of proliferative diabetic retinopathy

Recruiting
4
100
 
0.5mg ranibizumab injection after PPV ;1.0mg ranibizumab injection after PPV
Shanghai General Hospital; Shanghai General Hospital, Social donation
proliferative diabetic retinopathy
 
 
REBEL, NCT04991350: Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema

Terminated
4
5
RoW
Intravitreal ranibizumab, Lucentis, Intravitreal bevacizumab, Avastin
Cairo University
Diabetic Macular Edema, Macular Ischemia, Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression
09/22
11/22
ChiCTR2000035491: Efficacy and safety of Conbercept in the treatment of severe NPDR patients with DME: a prospective, multicenter, randomized controlled trial

Not yet recruiting
4
105
 
intravitreal injection of Conbercept ;panretinal photocoagulation
Shanghai General Hospital; Shanghai General Hospital, Major clinical research project of Shanghai Shenkang hospital development center
diabetic retinopathy
 
 
ChiCTR2100053595: Study on the effect of Qihuang Mingmu recipe on non-proliferative type 2 diabetic retinopathy

Recruiting
4
80
 
Basic treatment + Qihuang Mingmu Recipe ;Basic treatment
Affiliated Hospital of Nanjing University of Traditional Chinese Medicine (Jiangsu Provincial Hospital of Traditional Chinese Medicine); Affiliated Hospital of Nanjing University of Traditional Chinese Medicine (Jiangsu Provincial Hospital of Traditional Chinese Medicine), Innovation Development Fund of Affiliated Hospital of Nanjing University of Traditional Chinese Medicine (Y21023)
diabetic retinopathy
 
 
NCT05514925: Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy

Recruiting
4
60
RoW
Bevacizumab Injection [Avastin], IVB, Peripheral Retinal Cryoapplication, CRYO
Khairallah Moncef
Proliferative Diabetic Retinopathy, Vitreous Hemorrhage, Tractional Retinal Detachment
11/22
12/22
PROPER, NCT04674254: Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy

Completed
4
43
RoW
Bevacizumab Injection, Avastin, Targeted retinal photocoagulation, Standard pan-retinal photocoagulation
Cairo University
Proliferative Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression, Diabetic Retinopathy
03/23
03/23
NCT05386160: Phacoemulsification Combined With Intravitreal Injection of Ranibizumab Prevent Postoperative Capillary Non-perfusion Zone Progress in Non-proliferative Diabetic Retinopathy

Recruiting
4
96
RoW
Ranibizumab Injection [Lucentis], Phacoemulsification
Ruijin Hospital
Mild Non-proliferative Diabetic Retinopathy, Cataract Diabetic, Diabetic Retinopathy
03/23
03/23
ChiCTR2000030434: Intervention study of intravitreal injection of ranibizumab in the treatment of diabetic retinopathy

Recruiting
4
30
 
Intravitreal injection of thunderzumab
School of Ophthalmology & Optometry and Eye Hospital, Wenzhou Medical University; School of Ophthalmology & Optometry and Eye Hospital, Wenzhou Medical University, No
diabetic retinopathy
 
 
ChiCTR2100047351: Clinical study of intravitreal injection of conbercept in preventing postoperative complications of vitrectomy for diabetic retinopathy

Recruiting
4
90
 
Intravitreal injection of conbercept was performed 2 weeks after operation ;No intravitreal injection of conbercept was performed
Peking University Third Hospital; Peking University Third Hospital, Beijing Bethune Public Welfare Foundation
Diabetic retinopathy
 
 
ChiCTR2200061563: An Observational Study of Pars Plana Vitrectomy Combined with or Without Conbercept in the Treatment of Proliferative Diabetic Retinopathy

Not yet recruiting
4
516
 
Intravitreal injection of Conbercept before PPV + PPV ;Intravitreal injection of Conbercept at the end of PPV+PPV ;PPV without intravitreal injection of Conbercept
Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, China Ophthalmic Treatment Research Fund
Proliferative Diabetic retinopathy
 
 
LENS, NCT03439345 / 2016-002656-24: Lowering Events in Non-proliferative Retinopathy in Scotland

Completed
4
1151
Europe
Fenofibrate 145 mg, Placebo Oral Tablet
University of Oxford, National Institute for Health Research, United Kingdom, University of Glasgow, University of Aberdeen, University of Dundee, University of Edinburgh, NHS Scotland Diabetic Retinopathy Screening Collaborative
Diabetic Retinopathy
11/23
02/24
ChiCTR2300070172: Protective effect of diquafosol sodium eye drops on ocular surface tissue during perioperative period of vitrectomy for diabetic retinopathy: a prospective, multicenter, randomized controlled trial

Not yet recruiting
4
160
 
Diquafosol sodium eye drops and sodium hyaluronate eye drops were used 3 days before surgery, 1 drop/time, 3 times/day, until 1 month after surgery ;Sodium hyaluronate eye drops were used 3 days before surgery, 1 drop/time, 3 times/day until 1 month after surgery
Xuzhou First People's Hospital; Zhongguancun Precision Medicine Foundation, Zhongguancun Precision Medicine Foundation
diabetic retinopathy
 
 
NCT06305143: Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy

Recruiting
4
58
RoW
Conbercept
Shanghai Eye Disease Prevention and Treatment Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Diabetic Macular Edema
12/24
07/25
NCT06191094: Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy

Enrolling by invitation
4
100
US
Faricimab Injection, Vabysmo, sham treatment
University of Colorado, Denver
Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus
01/25
01/27
VOYAGE, NCT04708145: Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial

Active, not recruiting
4
150
US
Aflibercept Injection, Eylea
Greater Houston Retina Research, Regeneron Pharmaceuticals, Clinical Trials Resource Group, LLC
Diabetic Retinopathy
09/24
09/24
FYB203-04-01, NCT06708637: Ocular Safety and Usability Study for FYB203 PFS

Completed
4
30
US
FYB203 2 mg (0.05 mL of 40 mg/mL), aflibercept-mrbb
Formycon AG
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy
10/24
10/24
NCT06660940: Clinical Trial of Keluoxin Capsules in the Treatment of Diabetic Kidney Disease with Diabetic Retinopathy

Not yet recruiting
4
460
NA
Keluoxin Capsules, Keluoxin Capsule Simulants, Irbesartan
Chinese PLA General Hospital
Diabetic Kidney Disease, Diabetic Retinopathy
10/27
10/27
NCT05358080: Study to Evaluate Efficacy and Safety of Entelon 50mg in Patients With Non-Proliferative Diabetic Retinopathy

Recruiting
4
396
RoW
Entelon Tab. 50mg, Vitis Vinifera Seed Dreid Extract 50mg, Placebo
Hanlim Pharm. Co., Ltd.
Non Proliferative Diabetic Retinopathy
12/24
12/24
ChiCTR2200060038: Strategies in the treatment of conbercept plus PRP for diabetic retinopathy: a randomized controlled clinical trial

Recruiting
4
104
 
Standard PRP therapy was followed by intravitreal injection (IVC) of compacept ;The standard PRP is given before intravitreal conbercept
The Second Affiliated Hospital of Xi'an Jiaotong University; 157 Xiwu Road, Xincheng District, self-funded
diabetic retinopathy
 
 
ACTRN12607000225415: Efficacy of intravitreal triamcinolone acetonide before pan retinal photocoagulation for improvement of visual acuity and macular edema in diabetic retinopathy

Recruiting
3
60
 
Eye Research Center, Farabi Eye Hospital, Tehran University of medical sciences
Diabetic macular edema in severe non proliferative diabetic retinopathy (NPDR)or proliferative diabetic retinopathy(PDR)
 
 
ACTRN12618000697280: Evaluation of the evolution of patients with vitreous hemorrhage caused by proliferative diabetic retinopathy subjected to intravitreal injection of antivascular endothelial growth factor (bevacizumab)

Recruiting
3
60
 
Hospital Oftalmológico de Sorocaba, Hospital Oftalmológico de Sorocaba
proliferative diabetic retinopathy , vitreous hemorrhage
 
 
532-SD-PRP for SNPDR, ChiCTR-TRC-12002735: Randomized, parallel controlled, clinical-trial on 532nm-subthreshold diode short pulse panretinal photocoagulation for severe non-proliferative diabetic retinopathy

Completed
3
168
 
532nm-Subthreshold diode short pulse-PRP ;Traditional PRP treatment
Zhongshan Ophthaomic Center, Sun Yat-sen University; Level of the institution：, Zhongshan Ophthaomic Center, Sun Yat-sen University
Diabetic retin
 
 
2004-005197-23: Funktionelle Ergebnisse der intravitrealen Injektion von Triamcinolonacetonid im Vergleich zur konventionellen Lasertherapie bei diabetischem Makulaödem.

Ongoing
3
40
Europe
Triam-Hexal 40, TA, Triam-Hexal 40 (Triqmcinolon-acetonid), Triam-Hexal 40 (Triqmcinolon-acetonid)
Klinik und Poliklinik für Augenheilkunde der Universität Regensburg
Patients with diffuse macular edema due to diabetic retinopathy and decrease in visual acuity.
 
 
2010-022473-33: Short term effect of Lucentis® (Ranibizumab) as pretreatment to laser photocoagulation versus Lucentis® (Ranibizumab) combined with laser photocoagulation in the treatment of diabetic macular edema. A prospective, randomized study.

Ongoing
3
64
Europe
Lucentis 10 mg/ml, Lucentis 10 mg/ml
Department of Ophthalmology, Hietzing Hospital
Patients with macular edema due to diabetic retinopathy
 
 
ACTRN12618000202268: Comparing the effectiveness and safety of two treatments (OZURDEX® intravitreal implant versus Avastin®) for diabetic eye disease in adult Indigenous patients living in Western Australia.

Active, not recruiting
3
50
 
LIONS EYE INSTITUTE LTD, ALLERGAN AUSTRALIA PTY LTD
Diabetic Macular Oedema
 
 
2019-002591-14: FAME 1 Eye trial

Not yet recruiting
3
450
Europe
Fenofibrate, Tablet
Belfast Health & Social Care Trust, NHMRC Clinical Trials Centre
To evaluate the effects of once daily oral fenofibrate compared with placebo on clinically meaningful retinopathy progression over at least 3 years in adults with Type 1 diabetes (T1D) and existing diabetic retinopathy, Adult Type 1 diabetes with diabetic eye disease, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
PAVILION, NCT04503551: A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm

Hourglass Jan 2022 - Dec 2022 : Data from PAVILION trial for diabetic retinopathy
Active, not recruiting
3
174
US
PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection
Hoffmann-La Roche
Diabetic Retinopathy
10/22
06/25
NCT05310916: Effect of SGLT2i on Diabetic Retinopathy in Type 2 Diabetes Mellitus Patients

Recruiting
3
60
RoW
Dapagliflozin 10mg Tab plus another oral hypoglycemic agent, Diglifloz 10mg Tab, Two oral hypoglycemic agents other than dapagliflozin, Oral anti-diabetic agents
Nidae Alaa
Diabetic Retinopathy
05/23
11/23
NCT04278417: Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

Completed
3
689
Canada, Japan, US, RoW
Brolucizumab 6 mg, RTH258, Panretinal photocoagulation laser, PRP
Novartis Pharmaceuticals
Proliferative Diabetic Retinopathy
10/23
08/24
GLOW, NCT05066230 / 2020-001064-29: A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)

Terminated
3
253
Europe, US, RoW
KSI-301, Sham injection
Kodiak Sciences Inc
Non-proliferative Diabetic Retinopathy
08/23
08/23
NCT05138029: Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation

Recruiting
3
60
RoW
Ranibizumab Injection [Lucentis], Lucentis, Inner limiting membrane stripping, Dexamethasone intravitreal implant, Dexamethasone Implants
Affiliated Hospital of Nantong University
Diabetic Retinopathy
12/23
05/24
NCT06305416: A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema

Recruiting
3
70
RoW
Ranibizumab 10mg/ml Injection, Test Product, Lucentis, Reference Product
Incepta Pharmaceuticals Ltd, Institute for Developing Science and Health Initiatives, Bangladesh
Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Macular Degeneration, Retinal Disease, Retinal Degeneration
07/25
09/25
GLOW2, NCT06270836: A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

Active, not recruiting
3
255
US
Tarcocimab, Tarcocimab tedromer, KSI-301, Sham injection
Kodiak Sciences Inc
Diabetic Retinopathy
01/26
01/26
FAME 1 EYE, NCT01320345 / ACTRN12611000249954: The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.

Recruiting
3
450
Europe, RoW
Fenofibrate, Inert lactose placebo
University of Sydney, National Health and Medical Research Council, Australia, Juvenile Diabetes Research Foundation Australia, Mylan Pharmaceuticals Inc
Type 1 Diabetes Mellitus, Diabetic Retinopathy, Diabetic Nephropathies
12/25
12/25
TNTL, NCT06817265: Clinical Study on the Efficacy and Safety of in the Treatment of Non-proliferative Diabetic Retinopathy

Not yet recruiting
3
360
NA
TNTL, TNTL simulation preparation
Beletalent (Zhuhai) Pharmaceutical Co., Ltd
Non-Proliferative Diabetic Retinopathy
08/26
12/26
FOCUS, NCT03811561 / 2017-003619-20: A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

Active, not recruiting
3
1500
Europe, Canada, US, RoW
Semaglutide, Placebo (semaglutide)
Novo Nordisk A/S
Diabetes Mellitus, Type 2
12/26
11/27
Protocol AF, NCT04661358: Fenofibrate for Prevention of DR Worsening

Recruiting
3
560
US
Fenofibrate, Placebo
Jaeb Center for Health Research, National Institutes of Health (NIH), National Eye Institute (NEI), Juvenile Diabetes Research Foundation, Roche Pharma AG, The Leona M. and Harry B. Helmsley Charitable Trust
Diabetic Retinopathy
04/29
04/29
ACTRN12616000737437: Regression of resilient neovessels with monthly anti-Vascular Endothelial Growth Factor (VEGF) treatment in laser treated proliferative diabetic retinopathy

Recruiting
2/3
100
 
Haytham Salti, Haytham Salti
diabetic retinopathy, proliferative diabetic retinopathy
 
 
ACTRN12615000118505: Is it possible to use long acting steroid preparations such as the dexamethasone intravitreal implant Ozurdex to prevent a deterioration in vision in patients with diabetes undergoing cataract surgery in central Australia.

Recruiting
2/3
40
 
Alice Springs Hospital, ALLERGAN AUSTRALIA PTY. LTD
Diabetic retinopathy, Diabetic macular edema, Cataract
 
 
2013-003272-12: Clinical Efficacy and Mechanistic Evaluation of Aflibercept for Proliferative Diabetic Retinopathy

Ongoing
2/3
220
Europe
Aflibercept, EMA/CHMP/299413/2012, Eylea, Eylea
Moorfields Eye Hospital, NIHR MRC - EME grant, Bayer PLC
Proliferative Diabetic Retinopathy (PDR)
 
 
NCT04511715: Intravitreal Bevacizumab for Nonproliferative Diabetic Retinopathy

Not yet recruiting
2/3
100
NA
Intravitreal Bevacizumab IVB, Follow-up with regular examination for determination of DR progression
Shahid Beheshti University of Medical Sciences
Non-proliferative Diabetic Retinopathy
01/21
11/21
PHOTON, NCT04429503 / 2019-003643-30: Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease

Completed
2/3
660
Europe, Canada, Japan, US, RoW
aflibercept, EYLEA®, BAY86-5321, High-dose aflibercept
Regeneron Pharmaceuticals, Bayer
Diabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
05/22
06/24
ACTRN12621001268831: The effect of tocotrienol-rich vitamin E (Tocovid Suprabio) compared to tocopherol on diabetic microvascular complications: A double-blinded placebo controlled, multicentre clinical trial

Not yet recruiting
2
200
 
Monash University Malaysia, Monash University Malaysia, HOVID Berhad, Malaysian Palm Oil Board (MPOB)
Diabetes Mellitus, Diabetic Nephropathy, Diabetic Retinopathy, Diabetic Neuropathy
 
 
ACTRN12611000063910: A phase II, 12 month, randomized, sham-controlled trial of ranibizumab (Lucentis) combined with grid laser compared with laser alone for the treatment of recalcitrant, diabetic macular oedema.

Recruiting
2
40
 
Novartis, Novartis
Diabetic Macular Oedema, Diabetic Retinopathy
 
 
ACTRN12619001568101: The Effects of Tocotrienol-Rich Vitamin E (Tocovid) on Diabetes and Diabetic Microvascular Complications: Kidney Disease (Nephropathy), Eye Disease (Retinopathy) and (Nerve Impariment (Neuropathy)

Recruiting
2
116
 
Monash University Malaysia, Monash University Malaysia, Fundamental Research Grant Scheme (FRGS), HOVID Berhad
Diabetes Mellitus, Diabetic Nephropathy, Diabetic Retinopathy, Diabetic Neuropathy
 
 
2013-004203-39: Study of efect of intravitreal aflibercept in subjects with prolipherative diabetic retinopathy

Ongoing
2
50
Europe
Solution for injection, Eylea
Fakultní nemocnice Královské Vinohrady, Fakultní nemocnice Královské Vinohrady
prolipherative diabetic retinopathy, advanced retinal changes by patients wits diabetes, Diseases [C] - Eye Diseases [C11]
 
 
2007-000658-30: Randomised controlled trial of Intravitreal Bevacizumab vs. conventional treatment for proliferative diabetic retinopathy.

Ongoing
2
20
Europe
Avastin (bevacizumab), Avastin (bevacizumab), Avastin (bevacizumab)
Royal Victoria Eye and Ear hospital
Proliferative diabetic retinopathy
 
 
2007-001553-26: A randomized, double-masked study with intraocular bevacizumab (Avastin®) compared with intraocular triamcinolone (Volon A®) in patients with clinical significant diabetic macular edema

Ongoing
2
30
Europe
Bevacizumab, triamcinolone, L01XX28, H02AB08, Avastin, Volon A, Avastin, Volon A
Vienna Medical University, Dept. of Ophthalmology
Patients with persisting macular edema due to diabetic retinopathy.
 
 
2013-001856-36: Efficacy and safety of Aflibercept (Eylea®) in proliferative diabetic retinopathy

Ongoing
2
40
Europe
aflibercept, Eylea® 40mg/ml, Eylea® 40mg/ml
CHU DE POITIERS, CHU DE POITIERS, BAYER
Percentage of patients showing regression of retinal neovascularization between baseline and month 12 in the Aflibercept group versus laser group
 
 
2014-001351-23: Efficacy Study of EG-Mirotin subcutaneously administered in multiple doses on diabetic macular edema in diabetic retinopathy patients. II.a fázisú, randomizált, placebo-kontrollos, kettős-vak, párhuzamos vizsgálat a szubkután több adagban alkalmazott EG-Mirotin (EGT022) hatásosságának értékelésére a diabeteses maculaödéma szempontjából, nem proliferatív diabeteses retinopathiában szenvedő betegeknél.

Ongoing
2
30
Europe
EG-Mirotin, Solution for injection
EyeGene, Inc, EYEGENE
diabetic retinopathy patients having early diabetic macular edema (DME), diabetic retinopathy, Diseases [C] - Eye Diseases [C11]
 
 
NCT04800679: Intravitreal Bevacizumab vs Laser vs Combination of Bevacizumab and Modified Laser in PDR

Recruiting
2
105
RoW
receive 4 monthly IVB injections and then rescue IVB, PRP group, IVB injections and a modified laser
Shahid Beheshti University of Medical Sciences
Proliferative Diabetic Retinopathy
07/20
12/21
2020-003865-20: A study that uses data from routine eye examinations of patients participating in studies FIDELIO-DKD and FIGARO-DKD to explore whether Finerenone can delay the progression of a diabetes complication that affects the eyes (diabetic retinopathy ,DR)

Not yet recruiting
2
90
Europe
Finerenone, BAY 94-8862 IR tablet 10 mg, Film-coated tablet
Bayer AG, Bayer AG
Diabetic Retinopathy, An eye condition called diabetic retinopathy (DR) that affects people with diabetes. People with DR have damage to the blood vessels in the tissue at the back of the eye called the retina., Diseases [C] - Cardiovascular Diseases [C14]
 
 
INFINITY, NCT04418427: ADVM-022 Intravitreal Gene Therapy for DME

Completed
2
36
US
6E11 vg/eye of ADVM-022, AAV.7m8-aflibercept, 2E11 vg/eye of ADVM-022, Aflibercept, Eylea
Adverum Biotechnologies, Inc.
Diabetic Macular Edema, Diabetic Retinopathy
11/22
11/22
ZETA-1, NCT04692688: Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy

Completed
2
103
US
APX3330, Placebo
Ocuphire Pharma, Inc.
Diabetic Retinopathy, Diabetic Macular Edema, NPDR - Non Proliferative Diabetic Retinopathy, PDR - Proliferative Diabetic Retinopathy
01/23
01/23
CANBERRA, NCT04265261 / 2019-002067-10: A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy

Completed
2
139
Europe, US, RoW
Placebo, RG7774
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd
Diabetic Retinopathy
07/23
07/23
2019-002067-10: A Study to Investigate the Efficacy and Safety of RG7774 in Patients with Diabetes Mellitus Type 1 or Type 2 with Treatment-naïve Diabetic Retinopathy

Not yet recruiting
2
135
Europe
RG7774, RG7774/F08, RG7774/F04, Film-coated tablet
F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd
Diabetic retinopathy, Diabetic retinopathy is a medical condition in which damage occurs to the retina due to diabetes mellitus., Diseases [C] - Eye Diseases [C11]
 
 
KALAHARI, NCT04527107 / 2019-001506-17: A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema

Completed
2
135
Europe, US, RoW
THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3, THR-149 0.13mg, THR-149 0.13mg + aflibercept 2mg, aflibercept 2mg + THR-149 0.13mg, Aflibercept 2mg
Oxurion, Oxurion NV
Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
09/23
11/23
NCT05642793: Effect of Postvitrectomy Proactive Use of Conbercept on Postoperative Complications in PDR Patients

Recruiting
2
80
RoW
proactive Anti-VEGF (conbercept) use, passive Anti-VEGF (conbercept) use
Peking University Third Hospital
Proliferative Diabetic Retinopathy
09/23
03/24
NCT05007262: Tangningtongluo Tablet in the Treatment of Non-proliferative Diabetic Retinopathy

Active, not recruiting
2
240
RoW
Tangningtongluo tablets, Calcium dobesilate capsules
Guizhou Bailing Group Pharmaceutical Co Ltd
Type2 Diabetes, Diabetic Retinopathy
10/23
12/23
NCT06181227: A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema

Terminated
2
21
US
AVD-104
Aviceda Therapeutics, Inc.
Diabetic Macular Edema, Diabetic Retinopathy
04/24
04/24
ChiCTR2100049803: Clinical study on the efficacy and safety of Tangningtongluo tablet in treating non proliferative diabetic retinopathy

Recruiting
2
240
 
Tangningtongluo tablets ;calcium hydroxyphenyl sulfonate capsule (Dasamine)
Ineye Hospital of Chendu University of TCM; Ineye Hospital of Chendu University of TCM, self-funded
diabetic retinopathy
 
 
NCT05429229: Effect of Topical Antioxidants in Dry Eye Disease and Diabetic Retinopathy

Recruiting
2
78
RoW
VisuXL®, VisuXL tear drop, Lagricel PF®, Lagricel preservative free, Humylub PF®, Humylub preservative free
Adolfo Daniel Rodriguez-Carrizalez, Hospital Civil de Guadalajara
Dry Eye Syndromes, Diabetic Retinopathy, Oxidative Stress, Tear Film Deficiency
12/23
01/24
NCT05383209: Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)

Completed
2
77
US
EYP-1901, Vorolanib, Sham IVT
EyePoint Pharmaceuticals, Inc.
Nonproliferative Diabetic Retinopathy
02/24
05/24
NCT05409235: Nesvategrast (OTT166) in Diabetic Retinopathy (DR)

Completed
2
225
US
OTT166, nesvategrast, Vehicle control
OcuTerra Therapeutics, Inc., Parexel
Diabetic Retinopathy
12/23
12/23
NEON-NPDR, NCT04722991 / 2020-002333-15: Non-proliferative Diabetic Retinopathy Treated With Runcaciguat

Completed
2
109
Europe, US, RoW
Runcaciguat (BAY1101042), Placebo
Bayer
Diabetic Retinopathy
03/24
04/24
ALTITUDE, NCT04567550: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)

Recruiting
2
130
US
ABBV-RGX-314 Dose 1, Genetic/ Combination Product, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, Topical Steroid, ABBV-RGX-314 Dose 4, Aflibercept
AbbVie, REGENXBIO Inc.
Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)
02/26
09/26
NCT04782128: Evaluation of RC28-E Injection in Diabetic Retinopathy

Active, not recruiting
2
120
RoW
RC28-E injection
RemeGen Co., Ltd.
Diabetic Retinopathy
05/24
07/24
NCT06321302: A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

Recruiting
2
178
Japan, US
BI 764524, Sham comparator to BI 764524, Aflibercept (Eylea®) - US only
Boehringer Ingelheim
Diabetic Retinopathy
07/26
11/26
Spectra, NCT05393284: Phase 2 Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy

Active, not recruiting
2
114
US
OPL-0401 Dose 1, Placebo
Valo Health, Inc.
Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
08/24
08/24
NCT06599684: Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy

Recruiting
2
24
US
INV-102
Invirsa, Inc.
Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy, Center-involved Diabetic Macular Edema, Center-involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
08/25
08/25
NCT06787482: Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies

Recruiting
2
100
RoW
ACE Retino
Ace Cells Lab Limited, European Wellness Academy
Retinitis Pigmentosa (RP), Age Related Macular Degeneration, Diabetic Retinopathy
06/25
12/25
NCT06003751: A Study of PER-001 in Participants with Diabetic Retinopathy

Active, not recruiting
2
24
US
PER-001 Intravitreal Implant - Low Dose, PER-001 Intravitreal Implant - High Dose, PER-001 Intravitreal Implant - Sham
Perfuse Therapeutics, Inc.
Diabetic Retinopathy
04/25
05/26
ASPIRE, NCT06011798: Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME

Active, not recruiting
2
52
US
Aflibercept, foselutoclax, UBX1325
Unity Biotechnology, Inc.
Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus, Diabetic Retinopathy, Retinal Degeneration, Retinal Diseases, Eye Diseases, Edema
03/25
06/25
NCT06770933: A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01

Recruiting
2
100
US, RoW
VX-01, Placebo
Vantage Biosciences Ltd, Vantage Biosciences Australia Pty Ltd
Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
03/27
03/27
TCM-MMI, NCT06813274: Multicenter RCT of Eye-Brain Imaging in Diabetes Neurovascular Coupling

Not yet recruiting
2
160
RoW
hypoglycemic treatment, Tangshen'an Granules, Ginkgo Leaf Tablets, Mecobalamin Tablets, placebo
Hejiang Ye
Diabetes Mellitus, Diabetic Retinopathy, Cognitive Impairment, Neurovascular Coupling
05/26
12/26
NCT03161652: Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema

Recruiting
2
120
RoW
DME lactose pill, placebo, sugar, DME levosulpiride, dopamine D2 receptor blocker, DR lactose pill, DR levosulpiride, DR vitrectomy lactose pill, DR vitrectomy levosulpiride, DME plus ranibizumab lactose pill, DME plus ranibizumab levosulpiride
Carmen Clapp, Instituto Mexicano de Oftalmologia (IMO), Universidad Autónoma de Querétaro, General Hospital Nuremberg & Paracelsus Medical University Nuremberg, Instituto de la Retina del Bajio SC (INDEREB), Instituto de Neurobiología, Universidad Nacional Autonoma de Mexico (UNAM)
Diabetic Macular Edema, Diabetic Retinopathy
12/25
06/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Diabetic Retinopathy
ChiCTR-TRC-12002122: Clinical study of Treatment with kudiezi Injection in nonproliferative diabetic retinopathy Patients

Completed
4
80
 
1. Therapy for diabetes mellitus: To control blood glucose, blood pressure, and serum lipid through drug, dietary management, exercise and education, taking calcium dobesilate tablets. 2 kudiezi injection. ;Basic therapy and placebo: 1. Therapy for diabetes mellitus: To control blood glucose, blood pressure, and serum lipid through drug, dietary management, exercise and education, taking calcium dobesilate tablets; 2. placebo
The Eye Hospital of Xingtai; The Eye Hospital of Xingtai, self-raised funds
nonproliferative diabetic retinopathy
 
 
ChiCTR-TRC-11001220: Study of Evaluation on the Clinical Efficacy of Tradition Chinese Medcine in the treatment of Non-proliferative diabetic retinopathy

Completed
4
60
 
Formula of T.C.M: benefit qi nourish Yin formula (granule ), 4.5g, oral, tid. Placebo:simulation formula(granule), 4.5g, oral, tid. ;Method:1.The period of alternate treatment uses the formula of T.C.M and placebo itself before and after cross-over study design. Each patient will receive two treatment matching cycle .The time of one treatment matching cycle is ten weeks. Each treatment matching cycle is made up of two treatment phase, including formula of T.C.M and placebo . Each treatment phase is made up of two period,the first period is medication period from 1st to 4th week, the second period
Chengdu University of Traditional Chinese Medicine; Level of the institution：, The Eleventh Five-year Plan Project of the Ministry of Science and Technology of China
Non-proliferative diabetic retinopathy
 
 
ChiCTR-TRC-12001975: Study on Efficacy and Safety of Treatment with Compound Danshen Dripping Pills (CDDP) in Type 2 diabetes

Completed
4
1500
 
Compound Danshen Dripping Pills (CDDP) ;Conventional treatment, not taking the compound Danshen Dripping Pill
Shengjing Hospital of China Medical University, and Affiliated Hospital of Liaoning University of Chinese Traditional Medicine; Shengjing Hospital of China Medical University, Tianjin Tasly pharmaceutical CO., LTD
diabetic retinopathy and / or diabetic nephropathy.
 
 
2013-004934-14: EVEROLIMUS VERSUS MYCOPHENOLIC ACID IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE DIFFERENCES IN RETINAL NEOVASCULARIZATION IN PATIENTS WITH DIABETIC RETINOPATHY EVEROLIMUS VERSUS MYKOFENOLOVÁ KYSELINA U PACIENTŮ PO KOMBINOVANÉ TRANSPLANTACI LEDVINY A SLINIVKY BŘIŠNÍ ZA ÚČELEM ZHODNOCENÍ VÝVOJE NOVOTVORBY CÉV NA SÍTNICI U PACIENTŮ S DIABETICKOU RETINOPATIÍ

Ongoing
4
60
Europe
Certican, Myfortic, Tablet, Certican, Myfortic
Institut klinické a experimentální medicíny, Institut klinické a experimentální medicíny
simultaneous pancreas/kidney allograft transplantation simultánní transplantace pankreatu a ledviny, simultaneous pancreas/kidney allograft transplantation simultánní transplantace pankreatu a ledviny, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04]
 
 
ChiCTR-IPR-16007848: A Randomized Controlled Trial of Conbercept Pretretreatment before Vitrectomy in Proliferative Diabetic Retinopathy

Completed
4
100
 
intravitreal conbercept injection
The First People's Hospital of Yunnan Province; The First People's Hospital of Yunnan Province, topic fund
diabetic retinopathy
 
 
ChiCTR-TRC-14005224: The Comparison of effects between Continuous Subcutaneous Insulin Infusion and add-on therapy with sitagliptin in Patients with newly diagnosed Type 2 Diabetes Mellitus

Recruiting
4
60
 
CSII alone ;CSII combined with sitagliptin
The Third Affiliated Hospital of Southern Medical University; Level of the institution：, the Science and Technology Commission of Guangdong Province, China
diabetes
 
 
2015-000959-24: Investigation of Eylea for patients with diabetic macular edema in an outpatient Setting.

Ongoing
4
50
Europe
Eylea, Injection, Eylea
Abteilung für Augenheilkunde, AKH Linz, Bayer
Diabetic Retinopathy and diabetic macular edema are leading causes for visual loss and blindness in young adults around the world., Diabetic Macular Edema, Diseases [C] - Eye Diseases [C11]
 
 
2014-005700-24: Cytokine Levels within patients with diabetic macular edema.

Ongoing
4
20
Europe
Lucentis, Ozurdex, EMEA/H/C/000715, EU/1/10/638/001, Injection, Intravitreal implant in applicator, Lucentis, Ozurdex
Abteilung für Augenheilkunde, AKH Linz, Bayer
Diabetic Retinopathy and diabetic macular edema are leading causes for visual loss and blindness in young adults around the world., Diabetic Macular Edema, Diseases [C] - Eye Diseases [C11]
 
 
2006-000082-10: The efficacy of oral transmucosal fentanyl as an analgesic agent during pan retinal photocoagulation (Pilot Study)

Ongoing
4
38
Europe
Oral transmucosal fentanyl, Actiq,
Aintree University Hospitals NHS Trust
Diabetic retinopathy - the commonest cause of blindness in the working age group in the United Kingdom. Retinal photocoagulation is a painful procedure, which forms the mainstay of treatment of diabetic retinopathy.
 
 
2017-000250-19: Effect of calcium dobesilate in early stages of diabetic retinopathy Efecto del dobesilato de calcio en estadios precoces de retinopatía diabética

Ongoing
4
60
Europe
Calcium dobesilate monohydrate, Capsule, Doxium 500
Fundació Hospital Universitari Vall d'Hebron - Institut de Recersa (VHIR), VIFOR OM PHARMA
Diabetic retinopathy Retinopatía diabética, Diabetic retinopathy Retinopatía diabética, Diseases [C] - Eye Diseases [C11]
 
 
ChiCTR-IIR-17010747: Effect study of Yuanqi Quyu Decoction on proliferative diabetic retinopathy after vitrectomy surgery

Recruiting
4
70
 
vitrectomy surgery with 2 months oral Yuanqi Quyu Decoction ;vitrectomy surgery only
Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region; Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region, Science and Technology Department of Urumqi
proliferative diabetic retinopathy
 
 
Conber-PDR, ChiCTR-IIR-17014160: Comparing different day regimes of preoperative Conbercept administration in proliferative diabetic retinopathy patients undergoing vitrectomy: a prospective randomized controlled clinical triaDat

Recruiting
4
120
 
Intravitreous injection of Conbercept 1 day before vitrectomy ;Intravitreous injection of Conbercept 3 days before vitrectomy ;Intravitreous injection of Conbercept 5 days before vitrectomy ;Intravitreous injection of Conbercept 7 days before vitrectomy ;Sham intravitreous injection of Conbercept 3 days before vitrectomy ;patients with macular hole receiving vitrectomy
The first affiliated hospital of Nanjing Medical University; The first affiliated hospital of Nanjing Medical University, National Key R&D Program of China (2017YFA0104101)
diabetic retinopathy
 
 
ChiCTR1800015751: Intravitreal conbercept at the end of diabetic vitrectomy for prevention of postoperative vitreous hemorrhage in proliferative diabetic retinopathy.

Recruiting
4
30
 
conbercept injection after surgery ;no injection after surgery
Eye and ENT hospital, Fudan University; Eye and ENT hospital, Fudan University, Bethune foundation
diabetic retinopathy
 
 
ChiCTR1800019292: A study for the effect of Jiahua Tablets on non-proliferative retinopathy of type 2 diabetes

Recruiting
4
80
 
Basic treatment + Jiahua Tablets ;Basic treatment
Affiliated Hospital of Nanjing University of Chinese Medicine(Jiangsu Province Hospital of Chinese Medicine); Level of the institution：, Innovative development funding of Affiliated Hospital of Nanjing University of Chinese Medicine (Y2018CX10)
diabetic retinopathy
 
 
ChiCTR-OPN-17011519: A prospective, controlled clinical trial of pharmacokinetics following subretinal and intravitreous anti-VEGF treatment

Recruiting
4
50
 
vitrectomy with saline tamponade and subretinal anti-VEGF injection ;vitrectomy with saline tamponade and intravitreous anti-VEGF injection ;vitrectomy with silicone oil tamponade and intravitreous anti-VEGF injection ;vitrectomy with gas tamponade and intravitreous anti-VEGF injection ;intravitreous anti-VEGF injection
Shanghai Jiaotong University Affiliated Ninth People's Hospital; Shanghai Ninth People’s Hospital, National Natural Science Foundation of China
diabetic retinopathy
 
 
ChiCTR2000031400: Evaluate the effect of anti VEGF injection on postoperative vitreous rebleeding during perioperative period of proliferative diabetic retinopathy

Recruiting
4
86
 
Ranibizumab ;none
Shanxi Eye Hospital; Shanxi Eye Hospital, Key Research and Development (R&D) Projects of Shanxi Province (201803D31184)
Diabetic Retinopathy
 
 
ChiCTR1900024203: Analysis of differences between preoperative and postoperative application of Conbercept in high-risk diabetic retinopathy patients without macular edema

Recruiting
4
100
 
Anti-vegf drugs were followed by PRP ;PRP, anti-vegf drug when necessary
Shandong Eye Institute; Shandong Eye Institute, Chengdu Kanghong Pharmaceutical Group Co.,Ltd.
diabetic retinopathy
 
 
ChiCTR2300067476: Study on the Effect of Different anti-VEGF drugs on Fibrovascular Membrane of Proliferative Diabetic Retinopathy

Completed
4
24
 
Ranibizumab ;Conbercept ;Aflibercept
Tianjin Medical University Eye Hospital; Tianjin Medical University Eye Hospital, Self-financing
diabetic retinopathy
 
 
NCT04464694: Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema

Not yet recruiting
4
142
RoW
Ranibizumab, Lucentis, Sham injection, Pars plana vitrectomy, Vitrectomy
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Novartis
Proliferative Diabetic Retinopathy, Diabetic Macular Edema
12/21
06/22
ChiCTR1900026328: Effect of Calcium Dobesilate on the Retinal Microcirculation and function in Patients with Diabetic Retinopathy

Recruiting
4
80
 
oral intake of Calcium Dobesilate，0.5g per time, 3 times per day for 12 weeks ;oral intake of placebo ,one capsule per time, 3 times per day for 12 weeks
Department of Ophthalmology, Guangdong Provincial People's Hospital; Department of Ophthalmology, Guangdong Provincial People's Hospital, Bethune-Merck Diabetes Research Fund
diabetic retinopathy
 
 
NCT04362241: DEXTENZA VS. PREDNISOLONE ACETATE 1% Macular Edema With Diabetic Retinopathy After Cataract Surgery

Recruiting
4
30
US
Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE], Prednisolone Acetate 1%
Ophthalmic Consultants of the Capital Region
Retinopathy, Diabetic
02/22
03/22
ChiCTR2100043399: A prospective randomized controlled study of long-acting dexamethasone implant to improve the prognosis of PDR patients after vitrectomy

Recruiting
4
75
 
Ozurdex ;anti-VEGF drugs ;no
Tianjin Medical University Eye Hospital; Tianjin Medical University Eye Hospital, Self-financing
diabetic retinopathy
 
 
OPEAXE, ChiCTR2000036080: Evaluation of the efficacy of dexamethasone sustained-release implant (Ozurdex) in patients with proliferative diabetic retinopathy complicated with diabetic macular edema (vitrectomy / silicone oil filling and silicone oil removal) in combination

Not yet recruiting
4
200
 
Intraoperative dexamethasone sustained release implant ;none
Beijing aier intech eye hospital; Beijing aier intech eye hospital, Self-financing
Diabetic retinopathy
 
 
NCT05832996: Cool vs Room-temperature Artificial Tears

Completed
4
124
US
Refresh Plus Preservative-free Lubricant Eye Drops
University of Iowa
Diabetic Retinopathy With Macular Edema of Both Eyes (Diagnosis), Central Retinal Vein Occlusion With Macular Edema, Exudative Age-Related Macular Degeneration, Unspecified Eye, Cystoid Macular Edema, Ocular Surface Disease, Dry Eye Sensation, Eye Pain
07/22
07/22
ChiCTR2000035032: Efficacy of different doses of anti-VEGF with vitrectomy in the treatment of proliferative diabetic retinopathy

Recruiting
4
100
 
0.5mg ranibizumab injection after PPV ;1.0mg ranibizumab injection after PPV
Shanghai General Hospital; Shanghai General Hospital, Social donation
proliferative diabetic retinopathy
 
 
REBEL, NCT04991350: Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema

Terminated
4
5
RoW
Intravitreal ranibizumab, Lucentis, Intravitreal bevacizumab, Avastin
Cairo University
Diabetic Macular Edema, Macular Ischemia, Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression
09/22
11/22
ChiCTR2000035491: Efficacy and safety of Conbercept in the treatment of severe NPDR patients with DME: a prospective, multicenter, randomized controlled trial

Not yet recruiting
4
105
 
intravitreal injection of Conbercept ;panretinal photocoagulation
Shanghai General Hospital; Shanghai General Hospital, Major clinical research project of Shanghai Shenkang hospital development center
diabetic retinopathy
 
 
ChiCTR2100053595: Study on the effect of Qihuang Mingmu recipe on non-proliferative type 2 diabetic retinopathy

Recruiting
4
80
 
Basic treatment + Qihuang Mingmu Recipe ;Basic treatment
Affiliated Hospital of Nanjing University of Traditional Chinese Medicine (Jiangsu Provincial Hospital of Traditional Chinese Medicine); Affiliated Hospital of Nanjing University of Traditional Chinese Medicine (Jiangsu Provincial Hospital of Traditional Chinese Medicine), Innovation Development Fund of Affiliated Hospital of Nanjing University of Traditional Chinese Medicine (Y21023)
diabetic retinopathy
 
 
NCT05514925: Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy

Recruiting
4
60
RoW
Bevacizumab Injection [Avastin], IVB, Peripheral Retinal Cryoapplication, CRYO
Khairallah Moncef
Proliferative Diabetic Retinopathy, Vitreous Hemorrhage, Tractional Retinal Detachment
11/22
12/22
PROPER, NCT04674254: Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy

Completed
4
43
RoW
Bevacizumab Injection, Avastin, Targeted retinal photocoagulation, Standard pan-retinal photocoagulation
Cairo University
Proliferative Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression, Diabetic Retinopathy
03/23
03/23
NCT05386160: Phacoemulsification Combined With Intravitreal Injection of Ranibizumab Prevent Postoperative Capillary Non-perfusion Zone Progress in Non-proliferative Diabetic Retinopathy

Recruiting
4
96
RoW
Ranibizumab Injection [Lucentis], Phacoemulsification
Ruijin Hospital
Mild Non-proliferative Diabetic Retinopathy, Cataract Diabetic, Diabetic Retinopathy
03/23
03/23
ChiCTR2000030434: Intervention study of intravitreal injection of ranibizumab in the treatment of diabetic retinopathy

Recruiting
4
30
 
Intravitreal injection of thunderzumab
School of Ophthalmology & Optometry and Eye Hospital, Wenzhou Medical University; School of Ophthalmology & Optometry and Eye Hospital, Wenzhou Medical University, No
diabetic retinopathy
 
 
ChiCTR2100047351: Clinical study of intravitreal injection of conbercept in preventing postoperative complications of vitrectomy for diabetic retinopathy

Recruiting
4
90
 
Intravitreal injection of conbercept was performed 2 weeks after operation ;No intravitreal injection of conbercept was performed
Peking University Third Hospital; Peking University Third Hospital, Beijing Bethune Public Welfare Foundation
Diabetic retinopathy
 
 
ChiCTR2200061563: An Observational Study of Pars Plana Vitrectomy Combined with or Without Conbercept in the Treatment of Proliferative Diabetic Retinopathy

Not yet recruiting
4
516
 
Intravitreal injection of Conbercept before PPV + PPV ;Intravitreal injection of Conbercept at the end of PPV+PPV ;PPV without intravitreal injection of Conbercept
Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, China Ophthalmic Treatment Research Fund
Proliferative Diabetic retinopathy
 
 
LENS, NCT03439345 / 2016-002656-24: Lowering Events in Non-proliferative Retinopathy in Scotland

Completed
4
1151
Europe
Fenofibrate 145 mg, Placebo Oral Tablet
University of Oxford, National Institute for Health Research, United Kingdom, University of Glasgow, University of Aberdeen, University of Dundee, University of Edinburgh, NHS Scotland Diabetic Retinopathy Screening Collaborative
Diabetic Retinopathy
11/23
02/24
ChiCTR2300070172: Protective effect of diquafosol sodium eye drops on ocular surface tissue during perioperative period of vitrectomy for diabetic retinopathy: a prospective, multicenter, randomized controlled trial

Not yet recruiting
4
160
 
Diquafosol sodium eye drops and sodium hyaluronate eye drops were used 3 days before surgery, 1 drop/time, 3 times/day, until 1 month after surgery ;Sodium hyaluronate eye drops were used 3 days before surgery, 1 drop/time, 3 times/day until 1 month after surgery
Xuzhou First People's Hospital; Zhongguancun Precision Medicine Foundation, Zhongguancun Precision Medicine Foundation
diabetic retinopathy
 
 
NCT06305143: Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy

Recruiting
4
58
RoW
Conbercept
Shanghai Eye Disease Prevention and Treatment Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Diabetic Macular Edema
12/24
07/25
NCT06191094: Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy

Enrolling by invitation
4
100
US
Faricimab Injection, Vabysmo, sham treatment
University of Colorado, Denver
Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus
01/25
01/27
VOYAGE, NCT04708145: Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial

Active, not recruiting
4
150
US
Aflibercept Injection, Eylea
Greater Houston Retina Research, Regeneron Pharmaceuticals, Clinical Trials Resource Group, LLC
Diabetic Retinopathy
09/24
09/24
FYB203-04-01, NCT06708637: Ocular Safety and Usability Study for FYB203 PFS

Completed
4
30
US
FYB203 2 mg (0.05 mL of 40 mg/mL), aflibercept-mrbb
Formycon AG
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy
10/24
10/24
NCT06660940: Clinical Trial of Keluoxin Capsules in the Treatment of Diabetic Kidney Disease with Diabetic Retinopathy

Not yet recruiting
4
460
NA
Keluoxin Capsules, Keluoxin Capsule Simulants, Irbesartan
Chinese PLA General Hospital
Diabetic Kidney Disease, Diabetic Retinopathy
10/27
10/27
NCT05358080: Study to Evaluate Efficacy and Safety of Entelon 50mg in Patients With Non-Proliferative Diabetic Retinopathy

Recruiting
4
396
RoW
Entelon Tab. 50mg, Vitis Vinifera Seed Dreid Extract 50mg, Placebo
Hanlim Pharm. Co., Ltd.
Non Proliferative Diabetic Retinopathy
12/24
12/24
ChiCTR2200060038: Strategies in the treatment of conbercept plus PRP for diabetic retinopathy: a randomized controlled clinical trial

Recruiting
4
104
 
Standard PRP therapy was followed by intravitreal injection (IVC) of compacept ;The standard PRP is given before intravitreal conbercept
The Second Affiliated Hospital of Xi'an Jiaotong University; 157 Xiwu Road, Xincheng District, self-funded
diabetic retinopathy
 
 
ACTRN12607000225415: Efficacy of intravitreal triamcinolone acetonide before pan retinal photocoagulation for improvement of visual acuity and macular edema in diabetic retinopathy

Recruiting
3
60
 
Eye Research Center, Farabi Eye Hospital, Tehran University of medical sciences
Diabetic macular edema in severe non proliferative diabetic retinopathy (NPDR)or proliferative diabetic retinopathy(PDR)
 
 
ACTRN12618000697280: Evaluation of the evolution of patients with vitreous hemorrhage caused by proliferative diabetic retinopathy subjected to intravitreal injection of antivascular endothelial growth factor (bevacizumab)

Recruiting
3
60
 
Hospital Oftalmológico de Sorocaba, Hospital Oftalmológico de Sorocaba
proliferative diabetic retinopathy , vitreous hemorrhage
 
 
532-SD-PRP for SNPDR, ChiCTR-TRC-12002735: Randomized, parallel controlled, clinical-trial on 532nm-subthreshold diode short pulse panretinal photocoagulation for severe non-proliferative diabetic retinopathy

Completed
3
168
 
532nm-Subthreshold diode short pulse-PRP ;Traditional PRP treatment
Zhongshan Ophthaomic Center, Sun Yat-sen University; Level of the institution：, Zhongshan Ophthaomic Center, Sun Yat-sen University
Diabetic retin
 
 
2004-005197-23: Funktionelle Ergebnisse der intravitrealen Injektion von Triamcinolonacetonid im Vergleich zur konventionellen Lasertherapie bei diabetischem Makulaödem.

Ongoing
3
40
Europe
Triam-Hexal 40, TA, Triam-Hexal 40 (Triqmcinolon-acetonid), Triam-Hexal 40 (Triqmcinolon-acetonid)
Klinik und Poliklinik für Augenheilkunde der Universität Regensburg
Patients with diffuse macular edema due to diabetic retinopathy and decrease in visual acuity.
 
 
2010-022473-33: Short term effect of Lucentis® (Ranibizumab) as pretreatment to laser photocoagulation versus Lucentis® (Ranibizumab) combined with laser photocoagulation in the treatment of diabetic macular edema. A prospective, randomized study.

Ongoing
3
64
Europe
Lucentis 10 mg/ml, Lucentis 10 mg/ml
Department of Ophthalmology, Hietzing Hospital
Patients with macular edema due to diabetic retinopathy
 
 
ACTRN12618000202268: Comparing the effectiveness and safety of two treatments (OZURDEX® intravitreal implant versus Avastin®) for diabetic eye disease in adult Indigenous patients living in Western Australia.

Active, not recruiting
3
50
 
LIONS EYE INSTITUTE LTD, ALLERGAN AUSTRALIA PTY LTD
Diabetic Macular Oedema
 
 
2019-002591-14: FAME 1 Eye trial

Not yet recruiting
3
450
Europe
Fenofibrate, Tablet
Belfast Health & Social Care Trust, NHMRC Clinical Trials Centre
To evaluate the effects of once daily oral fenofibrate compared with placebo on clinically meaningful retinopathy progression over at least 3 years in adults with Type 1 diabetes (T1D) and existing diabetic retinopathy, Adult Type 1 diabetes with diabetic eye disease, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
PAVILION, NCT04503551: A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm

Hourglass Jan 2022 - Dec 2022 : Data from PAVILION trial for diabetic retinopathy
Active, not recruiting
3
174
US
PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection
Hoffmann-La Roche
Diabetic Retinopathy
10/22
06/25
NCT05310916: Effect of SGLT2i on Diabetic Retinopathy in Type 2 Diabetes Mellitus Patients

Recruiting
3
60
RoW
Dapagliflozin 10mg Tab plus another oral hypoglycemic agent, Diglifloz 10mg Tab, Two oral hypoglycemic agents other than dapagliflozin, Oral anti-diabetic agents
Nidae Alaa
Diabetic Retinopathy
05/23
11/23
NCT04278417: Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

Completed
3
689
Canada, Japan, US, RoW
Brolucizumab 6 mg, RTH258, Panretinal photocoagulation laser, PRP
Novartis Pharmaceuticals
Proliferative Diabetic Retinopathy
10/23
08/24
GLOW, NCT05066230 / 2020-001064-29: A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)

Terminated
3
253
Europe, US, RoW
KSI-301, Sham injection
Kodiak Sciences Inc
Non-proliferative Diabetic Retinopathy
08/23
08/23
NCT05138029: Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation

Recruiting
3
60
RoW
Ranibizumab Injection [Lucentis], Lucentis, Inner limiting membrane stripping, Dexamethasone intravitreal implant, Dexamethasone Implants
Affiliated Hospital of Nantong University
Diabetic Retinopathy
12/23
05/24
NCT06305416: A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema

Recruiting
3
70
RoW
Ranibizumab 10mg/ml Injection, Test Product, Lucentis, Reference Product
Incepta Pharmaceuticals Ltd, Institute for Developing Science and Health Initiatives, Bangladesh
Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Macular Degeneration, Retinal Disease, Retinal Degeneration
07/25
09/25
GLOW2, NCT06270836: A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

Active, not recruiting
3
255
US
Tarcocimab, Tarcocimab tedromer, KSI-301, Sham injection
Kodiak Sciences Inc
Diabetic Retinopathy
01/26
01/26
FAME 1 EYE, NCT01320345 / ACTRN12611000249954: The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.

Recruiting
3
450
Europe, RoW
Fenofibrate, Inert lactose placebo
University of Sydney, National Health and Medical Research Council, Australia, Juvenile Diabetes Research Foundation Australia, Mylan Pharmaceuticals Inc
Type 1 Diabetes Mellitus, Diabetic Retinopathy, Diabetic Nephropathies
12/25
12/25
TNTL, NCT06817265: Clinical Study on the Efficacy and Safety of in the Treatment of Non-proliferative Diabetic Retinopathy

Not yet recruiting
3
360
NA
TNTL, TNTL simulation preparation
Beletalent (Zhuhai) Pharmaceutical Co., Ltd
Non-Proliferative Diabetic Retinopathy
08/26
12/26
FOCUS, NCT03811561 / 2017-003619-20: A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

Active, not recruiting
3
1500
Europe, Canada, US, RoW
Semaglutide, Placebo (semaglutide)
Novo Nordisk A/S
Diabetes Mellitus, Type 2
12/26
11/27
Protocol AF, NCT04661358: Fenofibrate for Prevention of DR Worsening

Recruiting
3
560
US
Fenofibrate, Placebo
Jaeb Center for Health Research, National Institutes of Health (NIH), National Eye Institute (NEI), Juvenile Diabetes Research Foundation, Roche Pharma AG, The Leona M. and Harry B. Helmsley Charitable Trust
Diabetic Retinopathy
04/29
04/29
ACTRN12616000737437: Regression of resilient neovessels with monthly anti-Vascular Endothelial Growth Factor (VEGF) treatment in laser treated proliferative diabetic retinopathy

Recruiting
2/3
100
 
Haytham Salti, Haytham Salti
diabetic retinopathy, proliferative diabetic retinopathy
 
 
ACTRN12615000118505: Is it possible to use long acting steroid preparations such as the dexamethasone intravitreal implant Ozurdex to prevent a deterioration in vision in patients with diabetes undergoing cataract surgery in central Australia.

Recruiting
2/3
40
 
Alice Springs Hospital, ALLERGAN AUSTRALIA PTY. LTD
Diabetic retinopathy, Diabetic macular edema, Cataract
 
 
2013-003272-12: Clinical Efficacy and Mechanistic Evaluation of Aflibercept for Proliferative Diabetic Retinopathy

Ongoing
2/3
220
Europe
Aflibercept, EMA/CHMP/299413/2012, Eylea, Eylea
Moorfields Eye Hospital, NIHR MRC - EME grant, Bayer PLC
Proliferative Diabetic Retinopathy (PDR)
 
 
NCT04511715: Intravitreal Bevacizumab for Nonproliferative Diabetic Retinopathy

Not yet recruiting
2/3
100
NA
Intravitreal Bevacizumab IVB, Follow-up with regular examination for determination of DR progression
Shahid Beheshti University of Medical Sciences
Non-proliferative Diabetic Retinopathy
01/21
11/21
PHOTON, NCT04429503 / 2019-003643-30: Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease

Completed
2/3
660
Europe, Canada, Japan, US, RoW
aflibercept, EYLEA®, BAY86-5321, High-dose aflibercept
Regeneron Pharmaceuticals, Bayer
Diabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
05/22
06/24
ACTRN12621001268831: The effect of tocotrienol-rich vitamin E (Tocovid Suprabio) compared to tocopherol on diabetic microvascular complications: A double-blinded placebo controlled, multicentre clinical trial

Not yet recruiting
2
200
 
Monash University Malaysia, Monash University Malaysia, HOVID Berhad, Malaysian Palm Oil Board (MPOB)
Diabetes Mellitus, Diabetic Nephropathy, Diabetic Retinopathy, Diabetic Neuropathy
 
 
ACTRN12611000063910: A phase II, 12 month, randomized, sham-controlled trial of ranibizumab (Lucentis) combined with grid laser compared with laser alone for the treatment of recalcitrant, diabetic macular oedema.

Recruiting
2
40
 
Novartis, Novartis
Diabetic Macular Oedema, Diabetic Retinopathy
 
 
ACTRN12619001568101: The Effects of Tocotrienol-Rich Vitamin E (Tocovid) on Diabetes and Diabetic Microvascular Complications: Kidney Disease (Nephropathy), Eye Disease (Retinopathy) and (Nerve Impariment (Neuropathy)

Recruiting
2
116
 
Monash University Malaysia, Monash University Malaysia, Fundamental Research Grant Scheme (FRGS), HOVID Berhad
Diabetes Mellitus, Diabetic Nephropathy, Diabetic Retinopathy, Diabetic Neuropathy
 
 
2013-004203-39: Study of efect of intravitreal aflibercept in subjects with prolipherative diabetic retinopathy

Ongoing
2
50
Europe
Solution for injection, Eylea
Fakultní nemocnice Královské Vinohrady, Fakultní nemocnice Královské Vinohrady
prolipherative diabetic retinopathy, advanced retinal changes by patients wits diabetes, Diseases [C] - Eye Diseases [C11]
 
 
2007-000658-30: Randomised controlled trial of Intravitreal Bevacizumab vs. conventional treatment for proliferative diabetic retinopathy.

Ongoing
2
20
Europe
Avastin (bevacizumab), Avastin (bevacizumab), Avastin (bevacizumab)
Royal Victoria Eye and Ear hospital
Proliferative diabetic retinopathy
 
 
2007-001553-26: A randomized, double-masked study with intraocular bevacizumab (Avastin®) compared with intraocular triamcinolone (Volon A®) in patients with clinical significant diabetic macular edema

Ongoing
2
30
Europe
Bevacizumab, triamcinolone, L01XX28, H02AB08, Avastin, Volon A, Avastin, Volon A
Vienna Medical University, Dept. of Ophthalmology
Patients with persisting macular edema due to diabetic retinopathy.
 
 
2013-001856-36: Efficacy and safety of Aflibercept (Eylea®) in proliferative diabetic retinopathy

Ongoing
2
40
Europe
aflibercept, Eylea® 40mg/ml, Eylea® 40mg/ml
CHU DE POITIERS, CHU DE POITIERS, BAYER
Percentage of patients showing regression of retinal neovascularization between baseline and month 12 in the Aflibercept group versus laser group
 
 
2014-001351-23: Efficacy Study of EG-Mirotin subcutaneously administered in multiple doses on diabetic macular edema in diabetic retinopathy patients. II.a fázisú, randomizált, placebo-kontrollos, kettős-vak, párhuzamos vizsgálat a szubkután több adagban alkalmazott EG-Mirotin (EGT022) hatásosságának értékelésére a diabeteses maculaödéma szempontjából, nem proliferatív diabeteses retinopathiában szenvedő betegeknél.

Ongoing
2
30
Europe
EG-Mirotin, Solution for injection
EyeGene, Inc, EYEGENE
diabetic retinopathy patients having early diabetic macular edema (DME), diabetic retinopathy, Diseases [C] - Eye Diseases [C11]
 
 
NCT04800679: Intravitreal Bevacizumab vs Laser vs Combination of Bevacizumab and Modified Laser in PDR

Recruiting
2
105
RoW
receive 4 monthly IVB injections and then rescue IVB, PRP group, IVB injections and a modified laser
Shahid Beheshti University of Medical Sciences
Proliferative Diabetic Retinopathy
07/20
12/21
2020-003865-20: A study that uses data from routine eye examinations of patients participating in studies FIDELIO-DKD and FIGARO-DKD to explore whether Finerenone can delay the progression of a diabetes complication that affects the eyes (diabetic retinopathy ,DR)

Not yet recruiting
2
90
Europe
Finerenone, BAY 94-8862 IR tablet 10 mg, Film-coated tablet
Bayer AG, Bayer AG
Diabetic Retinopathy, An eye condition called diabetic retinopathy (DR) that affects people with diabetes. People with DR have damage to the blood vessels in the tissue at the back of the eye called the retina., Diseases [C] - Cardiovascular Diseases [C14]
 
 
INFINITY, NCT04418427: ADVM-022 Intravitreal Gene Therapy for DME

Completed
2
36
US
6E11 vg/eye of ADVM-022, AAV.7m8-aflibercept, 2E11 vg/eye of ADVM-022, Aflibercept, Eylea
Adverum Biotechnologies, Inc.
Diabetic Macular Edema, Diabetic Retinopathy
11/22
11/22
ZETA-1, NCT04692688: Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy

Completed
2
103
US
APX3330, Placebo
Ocuphire Pharma, Inc.
Diabetic Retinopathy, Diabetic Macular Edema, NPDR - Non Proliferative Diabetic Retinopathy, PDR - Proliferative Diabetic Retinopathy
01/23
01/23
CANBERRA, NCT04265261 / 2019-002067-10: A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy

Completed
2
139
Europe, US, RoW
Placebo, RG7774
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd
Diabetic Retinopathy
07/23
07/23
2019-002067-10: A Study to Investigate the Efficacy and Safety of RG7774 in Patients with Diabetes Mellitus Type 1 or Type 2 with Treatment-naïve Diabetic Retinopathy

Not yet recruiting
2
135
Europe
RG7774, RG7774/F08, RG7774/F04, Film-coated tablet
F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd
Diabetic retinopathy, Diabetic retinopathy is a medical condition in which damage occurs to the retina due to diabetes mellitus., Diseases [C] - Eye Diseases [C11]
 
 
KALAHARI, NCT04527107 / 2019-001506-17: A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema

Completed
2
135
Europe, US, RoW
THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3, THR-149 0.13mg, THR-149 0.13mg + aflibercept 2mg, aflibercept 2mg + THR-149 0.13mg, Aflibercept 2mg
Oxurion, Oxurion NV
Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
09/23
11/23
NCT05642793: Effect of Postvitrectomy Proactive Use of Conbercept on Postoperative Complications in PDR Patients

Recruiting
2
80
RoW
proactive Anti-VEGF (conbercept) use, passive Anti-VEGF (conbercept) use
Peking University Third Hospital
Proliferative Diabetic Retinopathy
09/23
03/24
NCT05007262: Tangningtongluo Tablet in the Treatment of Non-proliferative Diabetic Retinopathy

Active, not recruiting
2
240
RoW
Tangningtongluo tablets, Calcium dobesilate capsules
Guizhou Bailing Group Pharmaceutical Co Ltd
Type2 Diabetes, Diabetic Retinopathy
10/23
12/23
NCT06181227: A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema

Terminated
2
21
US
AVD-104
Aviceda Therapeutics, Inc.
Diabetic Macular Edema, Diabetic Retinopathy
04/24
04/24
ChiCTR2100049803: Clinical study on the efficacy and safety of Tangningtongluo tablet in treating non proliferative diabetic retinopathy

Recruiting
2
240
 
Tangningtongluo tablets ;calcium hydroxyphenyl sulfonate capsule (Dasamine)
Ineye Hospital of Chendu University of TCM; Ineye Hospital of Chendu University of TCM, self-funded
diabetic retinopathy
 
 
NCT05429229: Effect of Topical Antioxidants in Dry Eye Disease and Diabetic Retinopathy

Recruiting
2
78
RoW
VisuXL®, VisuXL tear drop, Lagricel PF®, Lagricel preservative free, Humylub PF®, Humylub preservative free
Adolfo Daniel Rodriguez-Carrizalez, Hospital Civil de Guadalajara
Dry Eye Syndromes, Diabetic Retinopathy, Oxidative Stress, Tear Film Deficiency
12/23
01/24
NCT05383209: Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)

Completed
2
77
US
EYP-1901, Vorolanib, Sham IVT
EyePoint Pharmaceuticals, Inc.
Nonproliferative Diabetic Retinopathy
02/24
05/24
NCT05409235: Nesvategrast (OTT166) in Diabetic Retinopathy (DR)

Completed
2
225
US
OTT166, nesvategrast, Vehicle control
OcuTerra Therapeutics, Inc., Parexel
Diabetic Retinopathy
12/23
12/23
NEON-NPDR, NCT04722991 / 2020-002333-15: Non-proliferative Diabetic Retinopathy Treated With Runcaciguat

Completed
2
109
Europe, US, RoW
Runcaciguat (BAY1101042), Placebo
Bayer
Diabetic Retinopathy
03/24
04/24
ALTITUDE, NCT04567550: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)

Recruiting
2
130
US
ABBV-RGX-314 Dose 1, Genetic/ Combination Product, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, Topical Steroid, ABBV-RGX-314 Dose 4, Aflibercept
AbbVie, REGENXBIO Inc.
Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)
02/26
09/26
NCT04782128: Evaluation of RC28-E Injection in Diabetic Retinopathy

Active, not recruiting
2
120
RoW
RC28-E injection
RemeGen Co., Ltd.
Diabetic Retinopathy
05/24
07/24
NCT06321302: A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

Recruiting
2
178
Japan, US
BI 764524, Sham comparator to BI 764524, Aflibercept (Eylea®) - US only
Boehringer Ingelheim
Diabetic Retinopathy
07/26
11/26
Spectra, NCT05393284: Phase 2 Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy

Active, not recruiting
2
114
US
OPL-0401 Dose 1, Placebo
Valo Health, Inc.
Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
08/24
08/24
NCT06599684: Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy

Recruiting
2
24
US
INV-102
Invirsa, Inc.
Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy, Center-involved Diabetic Macular Edema, Center-involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
08/25
08/25
NCT06787482: Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies

Recruiting
2
100
RoW
ACE Retino
Ace Cells Lab Limited, European Wellness Academy
Retinitis Pigmentosa (RP), Age Related Macular Degeneration, Diabetic Retinopathy
06/25
12/25
NCT06003751: A Study of PER-001 in Participants with Diabetic Retinopathy

Active, not recruiting
2
24
US
PER-001 Intravitreal Implant - Low Dose, PER-001 Intravitreal Implant - High Dose, PER-001 Intravitreal Implant - Sham
Perfuse Therapeutics, Inc.
Diabetic Retinopathy
04/25
05/26
ASPIRE, NCT06011798: Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME

Active, not recruiting
2
52
US
Aflibercept, foselutoclax, UBX1325
Unity Biotechnology, Inc.
Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus, Diabetic Retinopathy, Retinal Degeneration, Retinal Diseases, Eye Diseases, Edema
03/25
06/25
NCT06770933: A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01

Recruiting
2
100
US, RoW
VX-01, Placebo
Vantage Biosciences Ltd, Vantage Biosciences Australia Pty Ltd
Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
03/27
03/27
TCM-MMI, NCT06813274: Multicenter RCT of Eye-Brain Imaging in Diabetes Neurovascular Coupling

Not yet recruiting
2
160
RoW
hypoglycemic treatment, Tangshen'an Granules, Ginkgo Leaf Tablets, Mecobalamin Tablets, placebo
Hejiang Ye
Diabetes Mellitus, Diabetic Retinopathy, Cognitive Impairment, Neurovascular Coupling
05/26
12/26
NCT03161652: Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema

Recruiting
2
120
RoW
DME lactose pill, placebo, sugar, DME levosulpiride, dopamine D2 receptor blocker, DR lactose pill, DR levosulpiride, DR vitrectomy lactose pill, DR vitrectomy levosulpiride, DME plus ranibizumab lactose pill, DME plus ranibizumab levosulpiride
Carmen Clapp, Instituto Mexicano de Oftalmologia (IMO), Universidad Autónoma de Querétaro, General Hospital Nuremberg & Paracelsus Medical University Nuremberg, Instituto de la Retina del Bajio SC (INDEREB), Instituto de Neurobiología, Universidad Nacional Autonoma de Mexico (UNAM)
Diabetic Macular Edema, Diabetic Retinopathy
12/25
06/26
 

Download Options